Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8843279 | 1.00 | TP53 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL8843258 | 1.00 | TP53 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL22263512 | 1.00 | TP53 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL14185392 | 1.00 | TP53 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL8843220 | 1.00 | TP53 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL8632043 | 1.00 | TP53 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL8844066 | 1.00 | TP53 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL10838919 | 0.98 | TP53 (0.45) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL4438455 | 0.91 | ALDH1A1 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 | |
| SCHEMBL905471 | 0.91 | ALDH1A1 (0.44) | TP53FAAHCNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399422-B2 | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications | POLYPLUS-TRANSFECTION (FR) | 2013-03-19 | — | — | US | disclosed |
| CN-101631553-B | Compositions for transfection of oligonucleotides with gene silencing activity | POLYPLUS TRANSFECTION SA FR | 2012-10-17 | — | — | CN | disclosed |
| EP-2004156-B1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS TRANSFECTION SA (FR) | 2011-01-26 | — | — | EP | disclosed |
| US-20100048672-A1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS-TRANSFECTION (FR) | 2010-02-25 | — | — | US | disclosed |
| CN-101631553-A | Compositions for transfection of oligonucleotides with gene silencing activity and biological and therapeutic applications thereof | POLYPLUS TRANSFECTION SA | 2010-01-20 | — | — | CN | disclosed |
| EP-2004156-A2 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | Polyplus-Transfection SA (FR) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008004058-A2 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS-TRANSFECTION SA (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048672-A1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | C1R, C1S, C3AR1 | TP53 2530/4885FAAH 1120/4885CNR1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.